Arrhythmias and Conduction DisturbancesUsefulness of the CHA2DS2-VASc Score to Predict Mortality in Defibrillator Recipients
Section snippets
Methods
The study population consisted of all patients (n = 2,258) who underwent ICD device implantation at the hospitals of the University of Pittsburgh Medical Center from February 2002 to April 2014. Data collection was approved by the Institutional Review Board at the University of Pittsburgh Medical Center. Patients <18 years and those who were implanted with recalled ICD leads were excluded from this analysis. All demographic and clinical data at the time of implantation were extracted from the
Results
A total of 2,258 consecutive patients were included in this analysis. CHA2DS2-VASC scores were calculated based on data at the time of patients' initial operative procedure for ICD implantation. Patients' demographic and clinical data are detailed in Table 1. Over a mean follow-up of 5.4 ± 3.6 years (median 5.1 years), 1,195 patients (53%) died. Total number of patients and mortality outcomes stratified by CHA2DS2-VASC score are listed in Table 2. The mean CHA2DS2-VASC score was 3.15 ± 1.52
Discussion
In this study comprising of a cohort of 2,258 ICD recipients not involved in any device recalls or advisories, we demonstrate that the CHA2DS2-VASC score, well-validated for assessing the risk of thromboembolic events in patients with atrial fibrillation, is also a strong predictor of mortality in ICD recipients. Our findings demonstrate that higher CHA2DS2-VASC scores are associated with increased mortality in ICD recipients, even after controlling for unbalanced covariates between quartile
Disclosures
The authors have no conflicts of interest to disclose.
References (10)
- et al.
Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation
Chest
(2010) - et al.
Impact of the CHA2DS 2-VASc score on anticoagulation recommendations for atrial fibrillation
Am J Med
(2012) - et al.
Usefulness of the CHA2DS2-VASC score to predict adverse outcomes in patients having percutaneous coronary intervention
Am J Cardiol
(2016) - et al.
A new method of classifying prognostic comorbidity in longitudinal studies: development and validation
J Chronic Dis
(1987) - et al.
Applicability of a risk score for prediction of the long-term (8-year) benefit of the implantable cardioverter-defibrillator
J Am Coll Cardiol
(2012)
Cited by (10)
Risk stratification of cardiovascular complications using CHA<inf>2</inf>DS<inf>2</inf>-VASc and CHADS<inf>2</inf> scores in chronic atherosclerotic cardiovascular disease
2021, International Journal of CardiologyCitation Excerpt :The CHA2DS2-VASc score has been shown to have a modestly better discriminative ability than the CHADS2 score in AF, especially in lower risk groups [6,7]. CHA2DS2-VASc scores may also predict MACE in patients with other conditions, such as chronic obstructive pulmonary disease [8], those undergoing isolated coronary artery bypass grafting (CABG) surgery [9] or percutaneous coronary intervention [10], with heart failure [11], or with implantable cardiac defibrillators [12]. The Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) trial demonstrated that the combination therapy of rivaroxaban plus aspirin compared with aspirin reduced the risk of MACE with hazard ratio of 0.76 (95% CI: 0.66–0.86) and mortality with hazard ratio of 0.82 (95% CI: 0.71–0.96) in patients with chronic CAD and/or PAD [13].
Utility of CHA<inf>2</inf>DS<inf>2</inf>-VASc Score to Predict Mid-Term Clinical Outcomes in Hemodialysis Patients
2022, American Journal of NephrologyDoes CHA2DS2-VASc score predict mortality in chronic kidney disease?
2021, Internal and Emergency Medicine
List of Support/Grant Information: Seed money, Pittsburgh, Pennsylvania.
See page 86 for disclosure information.